Functional polymorphism of lncRNA <i>MALAT1</i> contributes to pulmonary arterial hypertension susceptibility in Chinese people
Yufeng Zhuo(Southern Medical University), Ying Cheng(Jilin Province Tumor Hospital), Qingchun Zeng(Southern Medical University), Guo‐Yang Li(Harvard University), Peng Zhang(Shenyang 242 Hospital), Qiang Xie(Southern Medical University)
Cited by 99
Related Papers
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2024|369